(Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, a spokesperson told Reuters, despite ...

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans. In June, the U.S. Food and Drug Administration (FDA) ...

Needham upgraded Gilead Sciences (NASDAQ:GILD) to Buy from Hold on Friday, citing a physical survey to suggest that the company’s new twice-yearly injectable for HIV prevention, Yeztugo, is on track ...

A new HIV prevention drug will be made available at a lower cost in over 100 low-income countries within two years — a move expected to give millions access to the breakthrough treatment and ...

Doctors at DAP Health have begun administering a new twice-a-year injectable HIV prevention medication, which was approved by the Food and Drug Administration in June. Gilead's drug lenacapavir ...

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able to gain favorable insurance coverage despite questions about how the Trump ...

An epidemic that's been sustained for 44 years might finally be quelled, with the milestone approval of the first HIV drug that offers 100% protection with its twice-yearly injections. It's a landmark ...

Oral preexposure prophylaxis (PrEP) has played a significant role in Australia’s reduction of new HIV infections, but experts have sounded the alarm over ongoing challenges. They suggested that new, ...

Protecting public health abroad benefits Americans. In a globalized world, diseases and their social and economic impacts do not stay within national boundaries. Increased rates of untreated HIV in ...

A new pre-exposure prophylaxis (PrEP) drug has shown promise as a once-monthly oral pill to help prevent HIV. PrEP plays a key part in reducing the number of new HIV infections by stopping the virus ...

Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not to add the former’s new HIV prevention drug, Yeztugo (lenacapavir), to its ...